BOSTON--(BUSINESS WIRE)--Strand Therapeutics, the programmable mRNA company developing curative therapies for cancer and other diseases, today announced the appointment of Colleen Wilson as Chief People Officer. Ms. Wilson joins Strand with more than 23 years of leadership and operational experience in Human Resources, having led organizational effectiveness initiatives as well as establishing talent, culture, and diversity and inclusion engagement practices for both public and private life sciences companies.
“We’re thrilled to welcome Colleen, a highly talented industry veteran to the Strand executive team,” said Jake Becraft, Ph.D., CEO & Co-Founder, Strand Therapeutics. “Colleen brings broad and extensive capabilities as an operational leader in developing strategies that attract top talent and establishing organizational culture practices for continued growth. I look forward to her contributions as we ensure Strand remains a destination for top talent, and a diverse, inclusive and collaborative environment for our employees.”
"People are critical to the success of any organization, and I've been incredibly impressed by the talent at Strand. I look forward to working with the entire Strand team, as the company advances its pipeline to bring the promise of mRNA-based therapeutics beyond vaccines to treat significant unmet medical needs such as cancer,” said Wilson. "I am honored and excited to be part of such a rapidly growing organization and in positioning Strand’s robust people-first culture for future growth."
Ms. Wilson’s was most recently SVP, Human Resources at Rheos Medicines and has also consulted for multiple public and private biotechnology companies at various stages of development. Prior to founding her own consulting firm, she was VP and Head of Human Resources at Chiasma, Inc. and also led the Human Resources function at Omni-Guide Surgical and Rib-X Pharmaceuticals (now Melinta Therapeutics). Ms. Wilson has also held HR roles at Infinity Pharmaceuticals, Genzyme Corporation, Targanta Therapeutics (acquired by Medicines Company) and Therion Biologics. She has an MBA from Babson College and a bachelor’s degree from the University of New Hampshire.
About Strand Therapeutics
Strand Therapeutics is a next-generation biotechnology company committed to transforming the lives of patients by developing first-in-class programmable mRNA therapeutics. Founded by leaders in mRNA-based synthetic biology at MIT, Strand is creating the first platform for programmable, long-acting mRNA therapeutics that are bioengineered to enable precise control of the location, timing, intensity, and duration of therapeutic activity. Strand’s mission is to develop improved treatment options for cancer and other life-threatening diseases. The company is headquartered in Boston, MA. For more information, visit www.strandtx.com. Follow us on Twitter @StrandTx.
